Related Experiment Video
Updated: Aug 15, 2026
Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
Low-dose aspirin in unexplained recurrent pregnancy loss: A systematic review and meta-analysis
Marianna Onori1, Giuliana Beneduce1, Matteo Figà1
1Facoltà di Medicina e Chirurgia Università Cattolica del Sacro Cuore Rome Italy.
Introduction:
Recurrent pregnancy loss (RPL), defined as two or more consecutive pregnancy losses before 24 weeks of gestation, affects approximately 1%-2% of couples of reproductive ages. Despite comprehensive diagnostic work-up, up to 40%-50% of cases remain unexplained (uRPL). Low-dose aspirin (LDA) (50, 75, or 80 mg) administration during pregnancy has been proposed as a potential treatment to improve obstetric outcomes in women with uRPL. However, its efficacy in preventing pregnancy loss remains unclear. The aim of this systematic review and meta-analysis was to evaluate the efficacy of LDA administration on the pregnancy outcomes of women with uRPL.
Methods:
We systematically searched for relevant studies in PubMed, Scopus, EMBASE, Google Scholar, and the Cochrane Library without language restriction from inception until April 2025. Randomized controlled trials (RCTs) that summarize the evidence regarding the effect of LDA on obstetric outcomes in women with uRPL were included. The counted data were analyzed using relative risk (RR) as the effect-size statistic, and each effect size was assigned its 95% confidence interval (CI). This study was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The primary outcome was the live birth rate (LBR), and secondary outcomes included preeclampsia and fetal growth restriction rates.
Results:
Three RCTs were included, involving a total of 656 participants. No significant improvements were observed in terms of LBR in uRPL treated with daily administration of a 50-80 mg aspirin compared to untreated uRPL women (RR = 0.97, 95% CI, 0.90-1.04, p = 0.37).
Conclusions:
Our findings suggested that a 50-80 mg daily dose of aspirin does not improve the LBR of women with uRPL. Further studies, specifically RCTs using a 150 mg dose of aspirin in uRPL, are needed to clarify the efficacy of acetylsalicylic acid in preventing placental insufficiency-related pregnancy loss.
Prospero Registration:
CRD420251024932.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins